Saturday 17 October 2026
Export HRMY’s income statement to Excel — free account
Harmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024. In the quarter to June 2026, revenue grew 30.3%, EPS grew 88.4%, free cash flow grew 16.5% and total debt fell 10.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.
38.20
0.07
−0.18%
Follow HRMY
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 4 | 5 | 7 |
+8 more TTM periods Free account |
| 20.46% | 17.86% | 20.75% | 25.93% | ||
| 14.61% | 12.51% | 13.98% | 17.38% | ||
ROIC |
29.70% | 27.66% | 50.40% | 42.60% | |
Return on Tangible Assets |
31.24% | 25.93% | 24.23% | 30.10% | |
Average Days of Receivables |
42.21 | 43.93 | 40.68 | 44.48 | |
Free Cash Flow per Share |
6.13 | 5.91 | 6.05 | 5.16 | |
Free Cash Flow |
355.08 | 341.97 | 347.89 | 296.89 | |
Capital Expenditures |
— | — | (0.31) | (0.72) | |
| Other line items | |||||
Cash ROIC |
19.50% | 20.00% | 19.23% | 17.71% | |
Accounts Receivable Turnover |
9.41 | 8.40 | 9.66 | 9.07 | |
Accounts Payable Turnover |
9.44 | 9.16 | 12.62 | 9.99 | |
Inventory Turnover |
37.87 | 36.15 | 31.60 | 26.70 | |
Average Days of Payables |
33.55 | 49.51 | 32.56 | 52.19 | |
Days of Inventory on Hand |
9.84 | 9.14 | 9.86 | 13.64 | |
Tax Rate |
(0.25) | (0.26) | (0.26) | (0.19) | |
Research and Development Expense of Revenue |
23.01% | 24.96% | 21.83% | 21.11% | |
Selling, General and Administrative Expense of Revenue |
28.39% | 30.51% | 31.33% | 29.27% | |
Share Based Compensation of Revenue |
4.26% | 4.78% | 5.17% | 5.45% | |
Interest Coverage |
17.12 | 13.49 | 14.23 | 14.74 | |
Operating CF/Net income |
1.96 | 2.35 | 2.19 | 1.60 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 15.83 | |
Capex/Depreciation |
0.00 | 0.00 | (0.01) | (0.03) | |
Revenue per Share |
16.57 | 15.55 | 15.11 | 14.35 | |
Operating CF per Share |
6.13 | 5.91 | 6.06 | 5.17 | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates